Anti-CD14 Antibody, FITC-Labeled

Only %1 left
Catalog #
101884
As low as $75 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

This anti-CD14 antibody is a purified recombinant antibody, which is labeled with fluorescein isothiocyanate (FITC). This antibody has been tested by flow cytometry for binding to human CD14 on the surface of CD14 CHO Recombinant Cell Line (BPS Bioscience #78335).

Synonyms
Monocyte differentiation antigen CD14, CD_antigen CD14
Product Info
Storage and Usage
Citations
Species
Human
Isotype
IgG1
Clonality
Monoclonal
Host Species/Expression System
HEK293
Purity

≥90%

Purification
Protein A affinity chromatography from HEK293 supernatant.
Format

Aqueous buffer solution.

Formulation

8 mM Phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, 0.09% Sodium Azide, 0.2% BSA, and up to 20% glycerol. May contain a protein stabilizer.

UniProt #
P08571
Label

Fluorescein isothiocyanate (FITC) is a derivative of fluorescein and has excitation and emission spectrum peak wavelengths of approximately 495 nm and 519 nm, causing it to fluoresce green.

Background

CD14 (Cluster of Differentiation-14) is a surface antigen expressed predominantly by monocytes and macrophages. It is considered a patterned recognition receptor (PRR), which recognizes pathogen markers. Specifically, CD14 acts as a co-receptor for lipopolysaccharides (LPS) found in the outer membrane of gram-negative bacteria. Through this interaction, CD14 supports initiation of the innate immune response during bacterial infection. CD14 also contributes toward immune responses to viral pathogens such as human respiratory syncytial virus (RSV) and may amplify the inflammatory response observed in severe cases of SARS-CoV-2 infection (COVID-19). Monoclonal antibodies against CD14 are currently undergoing clinical trial as a candidate treatment to limit severe inflammatory responses common in patients hospitalized with COVID-19.